Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across Formulations.
作者信息
Harden Cynthia L
出版信息
Epilepsy Curr. 2017 Jan-Feb;17(1):29-31. doi: 10.5698/1535-7511-17.1.29.
Abstract
摘要
相似文献
1
Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across Formulations.
Epilepsy Curr. 2017 Jan-Feb;17(1):29-31. doi: 10.5698/1535-7511-17.1.29.
2
Assessing bioequivalence of generic modified-release antiepileptic drugs.
Neurology. 2016 Apr 26;86(17):1597-604. doi: 10.1212/WNL.0000000000002607. Epub 2016 Mar 25.
3
Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
Clin Drug Investig. 2016 Apr;36(4):281-92. doi: 10.1007/s40261-015-0374-7.
4
Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
JAMA Netw Open. 2020 Feb 5;3(2):e200181. doi: 10.1001/jamanetworkopen.2020.0181.
5
Risks and benefits of generic antiepileptic drugs.
Neurologist. 2008 Nov;14(6 Suppl 1):S66-72. doi: 10.1097/01.nrl.0000340793.61037.09.
6
Current approaches to the use of generic antiepileptic drugs.
Epilepsy Behav. 2007 Aug;11(1):46-52. doi: 10.1016/j.yebeh.2007.03.014. Epub 2007 May 29.
7
A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.
J Pediatr Pharmacol Ther. 2018 Jul-Aug;23(4):277-292. doi: 10.5863/1551-6776-23.4.277.
8
Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
Clin Ther. 2005 Jul;27(7):1092-103. doi: 10.1016/j.clinthera.2005.07.008.
9
Differences in the oral bioavailability of three rafoxanide formulations in sheep.
J S Afr Vet Assoc. 1995 Dec;66(4):197-201.
引用本文的文献
1
Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.
Int J Bipolar Disord. 2018 May 1;6(1):10. doi: 10.1186/s40345-018-0118-8.
本文引用的文献
1
Trial Reporting in ClinicalTrials.gov - The Final Rule.
N Engl J Med. 2016 Nov 17;375(20):1998-2004. doi: 10.1056/NEJMsr1611785. Epub 2016 Sep 16.
2
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.
Emerg Infect Dis. 2016 Jun;22(6):949-55. doi: 10.3201/eid2206.151037.
3
Assessing bioequivalence of generic modified-release antiepileptic drugs.
Neurology. 2016 Apr 26;86(17):1597-604. doi: 10.1212/WNL.0000000000002607. Epub 2016 Mar 25.
4
Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Lancet Neurol. 2016 Apr;15(4):365-72. doi: 10.1016/S1474-4422(16)00014-4. Epub 2016 Feb 12.
5
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Epilepsia. 2015 Sep;56(9):1415-24. doi: 10.1111/epi.13095. Epub 2015 Jul 23.
6
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
BMJ. 2014 Apr 9;348:g2545. doi: 10.1136/bmj.g2545.
7
The imperative to share clinical study reports: recommendations from the Tamiflu experience.
PLoS Med. 2012;9(4):e1001201. doi: 10.1371/journal.pmed.1001201. Epub 2012 Apr 10.
8
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
BMJ. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106.
9
Cost-benefit of stockpiling drugs for influenza pandemic.
Emerg Infect Dis. 2005 Aug;11(8):1280-2. doi: 10.3201/eid1108.041156.
10
World is ill-prepared for "inevitable" flu pandemic.
Bull World Health Organ. 2004 Apr;82(4):317-8.
Zotero 插件